

Cover Story
News Analysis
For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes
- Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Pam Bondi diagnosed with thyroid cancer
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - As FDA’s wheels almost entirely come off, NCI remains sturdy—a cancer moonshot may even be on the horizon
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer


















